Nucleic Acid Based Therapeutics Market Size, Share & Trends Analysis Report By Product, By Application, By End-user, By Region, And Segment Forecasts, 2022 To 2030

Nucleic acid based therapeutics (NAT) target the genetic basis of the disease for treatment. Technological advancement and human genome understanding have allowed the development of many nucleic acids based therapeutics and even the approvals by US FDA and EMA demonstrates the potential to treat diseases genetically. NAT even allows long-lasting effects as it involves the cellular mechanism of gene silencing, addition, replacement, or editing.

The rising investments in the healthcare sector have also driven the research toward the treatment of many diseases and disorders. The increasing rate of chronic diseases among the population along with the genetic disorders has resulted in an upswing in research activities for building better healthcare settings worldwide. NAT offers a targeted and effective solution for any diseased condition. The COVID-19 pandemic also fueled the NAT market, as the successful utilization of mRNA vaccines as one of the preventive treatments boosted the healthcare industry to recognize the importance and efficacy of nucleic acid based therapies.

Nucleic acid based therapeutics market is segmented based on the following technologies;

• RNA targeted therapeutics,

• Gene therapies,

• Epigenetic and microRNA modulating therapies,

• Genome editing therapies,

• Others

Many approved and late stage clinical programs are using RNA targeted treatment platform. Use of ASO (antisense oligonucleotides) or siRNA (short interfering RNA) for treatment of muscular atrophy has been approved by FDA and EMA. The widespread knowledge of the human genome and thus the advent of gene therapies for development & clinical use approval has boosted in the past years. The well-used examples of Kymriah, Yescarta, Tecartus for treatment of types of leukemia or lymphoma demonstrates the growing use of gene therapies. Novel identification of therapeutic targets in the non-coding genome are arising from the epigenetics research. The importance of genome editing techniques via CRISPR/Cas has been established in many applications such as stem cell. These gene editing therapeutics are the next generation of NAT market. Furthermore, other technologies such as LNPs (lipid nanoparticles), adeno-associated virus (AAV) vectors and many more also hold some significance in the NAT market.

The advancement in molecular technologies and the continuous omics-based research has resulted in huge investments by many companies. The nucleic acid based therapeutics market is highly competitive and the market participation is via many strategic business models. Acquisitions, partnerships or collaborations are the leading revenue generators in the market. For instance, in August 2022, Merck & Co. announced that it has collaborated with Orna Therapeutics to develop a new class of therapeutic RNA. The collaboration involved the discovery, development and commercialization of new RNA-based therapeutics for vaccines, infectious disease as well as oncology programs. 

Some of the key players in the nucleic acid based therapeutics market are Silence Therapeutics plc, Ionis Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals, BioNtech, Moderna Inc., and Alnylam Pharmaceuticals, Inc. among others.